Damora Therapeutics (DMRA) Enterprise Value (2019 - 2026)

Damora Therapeutics has reported Enterprise Value for 8 years, with the latest figure at -$202.4 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value fell 1595.25% year-over-year to -$202.4 million; the trailing twelve-month figure through Mar 2026 stood at -$202.4 million (down 1595.25% YoY), and the FY2025 full-year result was -$257.6 million, down 1717.45% from the prior year.
• Enterprise Value for Q1 2026 stood at -$202.4 million, up from -$257.6 million in the prior quarter.
• The five-year high for Enterprise Value was -$7.6 million in Q3 2025, with the low at -$257.6 million in Q4 2025.
• Historically, Enterprise Value has averaged -$62.6 million across 5 years, with a median of -$52.1 million in 2023.
• Annual changes were most pronounced in 2024 — Enterprise Value surged 85.49% — and 2025, when it plunged 1717.45%.
• Damora Therapeutics' Enterprise Value stood at -$60.2 million in 2022, then surged by 38.59% to -$37.0 million in 2023, then jumped by 61.67% to -$14.2 million in 2024, then sank by 1717.45% to -$257.6 million in 2025, then climbed by 21.44% to -$202.4 million in 2026.
• The last three Enterprise Value figures came in at -$202.4 million (Q1 2026), -$257.6 million (Q4 2025), and -$7.6 million (Q3 2025), per Business Quant data.